Release date: February 1, 2022
Valid through: January 31, 2024
Estimated Time to Complete Activity: 2 hours, 30 minutes
This activity has been designed to meet the educational needs of physicians, advanced practice clinicians, nursing professionals, pharmacists, psychologists, social workers, rehabilitation specialists, dietitians, researchers, advocates, and other members of the healthcare team involved in the management of patients with MS, conduct research in MS or who have a special interest in MS.
Session 3 of Fundamentals of Multiple Sclerosis Care offers an insight into multidisciplinary considerations to include DMTs, practical nursing approaches to infusible therapies, role of specialty pharmacists in MS medication side effect management and a review of emerging therapies.
Topics and Faculty
- Welcome and Overview of Program – Beverly Layton, RN, CCRC, MSCN
- Current Treatments – John R. Rinker, II, MD
- Ask the Infusion Nurse – Marie Moore, MSN, FNP, MSCN
- MS Medication Side Effect Management – Erica Goff, PharmD, BCPS, MSCS
- Emerging Therapies – Lori Mayer, DNP, APRN, NP-C, RN, MSN, MSCN
Upon completing this activity, participants should be better able to:
- Examine the various models of care in MS and the roles and responsibilities of care team members in order to adapt the most appropriate model for team-based care in a given practice setting.
- Integrate the complex processes that support the provision of team-based, comprehensive care in MS into effective practices and centers providing evidence-based MS care.
- Integrate information about the mechanisms underlying MS relapses, progression, and gray and white matter pathology as the basis for monitoring and treating the disease.
- Summarize methods to monitor treatment outcomes including patient self-report, automated self-assessment, new clinician reported outcomes, imaging, and biomarkers in order to optimize their utilization in clinical practice and research.
- Analyze and integrate the conceptual framework under which MS nurses construct individualized interventions and monitor outcomes in the care of patients with MS.
- Evaluate current nursing practice in various models of care utilized in settings in North America and internationally.
- Incorporate specific and evidence-based nursing skills into the development of team-based plans for individualized care of patients and families affected by MS.
- Analyze common symptoms of MS and their appropriate pharmacologic and non-pharmacologic interventions in order to develop strategies designed to maximize function and quality of life.
- Identify assessment techniques to isolate those factors that affect the manifestation of the complex symptomatology of MS and differentiate between acute and chronic MS symptoms.
Accreditation and Credit Designation
In support of improving patient care, The Consortium of Multiple Sclerosis Centers is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Consortium of Multiple Sclerosis Centers designates this enduring material for a maximum of 2.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Consortium of Multiple Sclerosis Centers designates this enduring material for 2.5 nursing continuing professional development (NCPD) credits.
This knowledge-based activity (UAN JA4008165-0000-22-009-H01-P) qualifies for 2.5 contact hour (.25 CEUs) of continuing pharmacy education credit.
Physician Assistants (PAs)
The Consortium of Multiple Sclerosis Centers has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.5 AAPA Category 1 CME credits. Approval is valid until January 31, 2024. PAs should only claim credit commensurate with the extent of their participation.
The activity is awarded 2.5 CE credits.
Social Workers (Through ASWB’s ACE Program) (SW)
As a Jointly Accredited Organization, the CMSC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. The CMSC maintains responsibility for this course. Social workers completing this course receive 2.5 continuing education credits.
Certificate of Attendance for Other Healthcare Professionals
A Certificate of Attendance will be given upon completion of course requirements enabling participants to register their credit with the appropriate licensing boards or associations. Participants may apply for other accreditations using procedures established by specific organizations.
Disclosure of Financial Relationships
In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Continuing Education, CMSC requires that individuals in a position to control the content of an educational activity disclose all financial relationships with ineligible companies. CMSC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, CMSC seeks to verify that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. CMSC is committed to providing learners with high-quality CE activities that promote improvements in health care and not those of a commercial interest.
The program faculty reported the following relevant financial relationships with ineligible companies:
- Erica Goff, PharmD, BCPS, MSCS has disclosed no relevant financial relationships with ineligible companies.
- Beverly Layton, RN has disclosed the following relevant financial relationships with ineligible companies: Consultant: Biogen, Sanofi Genzyme, Novartis, Banner Life Sciences; Speakers Bureau: Sanofi/Genzyme.
- Lori Mayer, DNP, APRN, NP-C, MSN, RN, MSCN has disclosed the following relevant financial relationships with ineligible companies: Advisory Board: Bristol Myers Squibb, TG Therapeutics.
- Marie Moore, MSN, FNP, MSCN has disclosed the following relevant financial relationships with ineligible companies: Advisory Board: Sanofi Genzyme, TG Therapeutics.
- John R. Rinker, II, MD has disclosed no relevant financial relationships with ineligible companies.
All of the relevant financial relationships listed for these individuals have been mitigated.
The planners, reviewers, editors, staff, or other members of CMSC who are in a position to control content have disclosed no relevant financial relationships.
This activity is best viewed using the latest version of Chrome, Edge, or Firefox.
Method of Participation
To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) view the educational activity, and (3) complete the activity evaluation.
How to Claim Credit
- To complete the evaluation and claim credit, go to www.highmarksce.com/mscare/
- Create a new account or log in with your user name and password*.
- Select the Enduring Materials tab, then select this activity from the listing and follow the instructions to complete the activity and receive your credit.
*If you forgot your username or password, click on Forgot password. You will receive an email with a link to change your password.
There are no fees to participate in this activity.
Disclosure of Unlabeled Use
CMSC requires faculty to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Commercial Support Acknowledgment
CMSC has not received commercial support for this activity.
CMSC presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. CMSC assumes no liability for the information herein.
If you have any questions about this activity, please contact the CMSC at [email protected].